

# ForPatients

by Roche

[Early Breast Cancer](#) [Breast Cancer](#) [Er-Positive Breast Cancer](#) [HER-2 Negative Breast Cancer](#)

## **A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (IidERA Breast Cancer)**

**Trial Status**  
Recruiting

**Trial Runs In**  
54 Countries

**Trial Identifier**  
NCT04961996  
2021-000129-28,2023-507172-44-00  
GO42784

---

*The source of the below information is the publicly available website [ClinicalTrials.gov](#). It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with endocrine therapy of physician's choice in participants with medium- and high-risk Stage I-III histologically confirmed estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. In addition, an open-label exploratory substudy will explore the safety and efficacy of giredestrant in combination with abemaciclib in a subset of the primary study population.

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

---

**NCT04961996 2021-000129-28,2023-507172-44-00 GO42784**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
>=18 Years

**Healthy Volunteers**  
No

---